Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment

Journal of Neurochemistry

Volumn 79, Issue 1, 2001, Pages 152-160

  Gluck, Martin R ^a,b,c,d   Moy, Lily Y ^c   Jayatilleke, Elizabeth ^a,b   Hogan, Kelly A ^c   Manzino, Lawrence ^c   Sonsalla, Patricia K ^c  

^a Bronx Veterans Medical CenterBronx ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Dopamine; Methamphetamine; Neurotoxicity; Protein carbonyls; Seretonin; TBARs

Indexed keywords

BRAIN MONOAMINE; CARBONYL DERIVATIVE; DOPAMINE; LIPID; METHAMPHETAMINE; PROTEIN; REACTIVE OXYGEN METABOLITE; SEROTONIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; FRONTAL CORTEX; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MOUSE; NERVE ENDING; NEUROTOXICITY; NONHUMAN; NORADRENERGIC SYSTEM; OXIDATIVE STRESS; PRIORITY JOURNAL;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BIOGENIC MONOAMINES; BIOLOGICAL MARKERS; BRAIN; CEREBELLUM; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; HIPPOCAMPUS; HYDROXYINDOLEACETIC ACID; LIPID PEROXIDATION; MALE; METHAMPHETAMINE; MICE; NERVE TISSUE PROTEINS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SEROTONIN; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0034791072     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00549.x     Document Type: Article

References (49)

1. Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum
2. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents
3. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease
4. Parenterally administered 3-nitropropionic acid and amphetamine can combine to produce damage to terminals and cell bodies in the striatum
5. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration
6. Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines
7. Free radicals and the pathobiology of brain dopamine systems
8. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice
9. Alpha-Phenyl-N-tert-butyl nitrone attenuates methamphetamine-induced depletion of striatal dopamine without altering hyperthermia
10. Rapid ATP loss caused by methamphetamine in the mouse striatum: Relationship between energy impairment and dopaminergic neurotoxicity
11. Methamphetamine-induced neuronal damage: A possible role for free radicals
12. Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity
13. Methamphetamine neurotoxicity: Dissociation of striatal dopamine terminal damage from parietal cortical cell body injury
14. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
15. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration
16. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: Impact of methamphetamine
17. CNS oxidative stress associated with the kainic acid rodent model of experimental epilepsy
18. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro
19. Methamphetamine selectively alters brain glutathione
20. Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: Attenuation in CuZn-superoxide dismutase transgenic mice
21. Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain
22. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: Disparity between homogenates and vesicle preparations
23. Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: Protective effects of peroxynitrite decomposition catalyst
24. Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: Evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase
25. Hydroxyl radical formation following methamphetamine administration to rats
26. Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice
27. Molecular footprints of neurotoxic amphetamine action
28. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine
29. Determination of carbonyl content in oxidatively modified proteins
30. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): A putative nigral endotoxin of relevance to Parkinson's disease
31. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity
32. Protein measurement with folin reagent
33. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35,428
34. The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: The role of mitochondrial complex I and reactive oxygen species revisited
35. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse
36. Competitive and noncompetitive N-methyl-D-aspartate antagonists protect dopaminergic and serotonergic neurotoxicity produced by methamphetamine in various brain regions
37. Mechanisms of radical production
38. Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants
39. Amphetamine: Effects on catecholamine systems and behavior
40. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity
41. Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice
42. Treatment of mice with methamphetamine produces cell loss in the substantia nigra
43. Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons
44. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport
45. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers
46. Systemic administration of D-amphetamine induces long-lasting oxidative stress in the rat striatum
47. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users
48. Oxidation of serotonin by superoxide radical: Implications to neurodegenerative brain disorders
49. The effects of methamphetamine on the production of free radicals and oxidative stress